CSL Ltd (ASX:CSL) has seen its net profits rise by 6% in the first half of the 2025 fiscal year, driven by growing revenue from its CSL Behring business, which is responsible for plasma products and gene therapies.

The company’s net profit after tax had risen 6% to US$2.01 billion (or AU$3.2B) during 1H FY2025, with revenue rising by 5% to US$8.48B, and net guidance on track – remaining between US$3.2B and US$3.3B.

Looking at the CSL Behring business specifically, its revenue had risen 10% during the period, to $5,743 million, with a standout performance in Immunoglobulin (Ig) product sales, which had increased 15% to $3,174 million, with strong growth in multiple locations worldwide.

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring,” CEO and managing director Dr Paul McKenzie said, adding this was just one arm in which customer demand was evident.

“Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise.

“We continue to advance key initiatives to improve gross margin, which is tracking according to our plans.

“CSL Seqirus was negatively impacted by significantly low influenza immunisation rates, particularly in the U.S. CSL Vifor grew sales, underpinned by robust iron volumes in Europe and the expansion of our nephrology products.”

CSL’s interim dividend was US$1.30 per share (or A$2.08 per share), a rise of 16%.

CSL has been trading at $270.34.

Join the discussion: See what HotCopper users are saying about CSL Limited and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.